GC Cell Administers First CAR-NK Treatment to Gastric and Gastroesophageal Junction Cancer Patients
Launch of Advanced Regenerative Medicine Clinical Study for Advanced HER2-Positive Patients
Evaluation of Safety and Initial Efficacy of HER2-Targeted Allogeneic CAR-NK Cell Therapy
GC Cell has begun clinical development targeting solid tumors by administering its HER2-targeted CAR-NK cell therapy, 'AB-201', to the first patient.
On May 19, GC Cell announced that AB-201 was administered for the first time to patients with advanced HER2-positive gastric cancer and gastroesophageal junction cancer as part of an advanced regenerative medicine clinical study led by Professor Jung Minkyu's research team at Severance Hospital.
This study aims to evaluate the safety and initial anti-tumor activity of AB-201 in patients with advanced HER2-positive cancer who have limited treatment options after standard therapies.
AB-201 is an allogeneic HER2-targeted CAR-NK cell therapy based on GC Cell's proprietary CAR-NK platform. It is a solid tumor pipeline designed to selectively attack tumor cells that overexpress HER2. Considering that previous CAR-NK development in Korea has primarily focused on hematologic malignancies, this first patient administration signifies the expansion of GC Cell's CAR-NK platform into solid tumors.
Professor Jung stated, "HER2-positive gastric cancer and gastroesophageal junction cancer are areas with high unmet medical needs even after standard treatments. Through this study, we plan to confirm the safety and clinical applicability of CAR-NK cell therapy."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- Foreign Investors Sell 6 Trillion Won Net... KOSPI Closes Below 7,200
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
GC Cell CEO Won Sungyong said, "AB-201 is a key pipeline for expanding GC Cell's CAR-NK platform technology into the solid tumor field. With this first patient administration, we will accelerate the development of a new immunocellular therapy approach for patients with HER2-positive solid tumors and further advance AB-201 into a globally competitive cell therapy product."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
